Clinical Trial Update: Lenalidomide With or Without Rituximab in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating lenalidomide with or without rituximab in relapsed or refractory chronic lymphocytic leukemia has completed and results were posted in …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Chronic Lymphocytic Leukemia

Drugs mentioned

• Revlimid (lenalidomide)
• Rituxan (rituximab)

Snippet

Sponsor: Roswell Park Cancer Institute | Conditions: Leukemia | Phase 2 | Status: COMPLETED | Results posted: 2017-07-11